Clinical trial
A Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer
NCT05271318 is registered in ClinicalTrials.gov with TILT Biotherapeutics Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Two-part, Phase I/Ib, Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase I Part) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase Ib Part) in Patients With Platinum Resistant or Refractory Ovarian Cancer
- Lead sponsor
- TILT Biotherapeutics Ltd.
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- May 17, 2022
- Completion date
- August 31, 2027
- Enrollment
- 29 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
platinum-refractory fallopian tube carcinoma, platinum-refractory ovarian carcinoma, platinum-refractory primary peritoneal carcinoma, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian cancer, platinum-resistant primary peritoneal carcinoma, platinum-sensitive fallopian tube carcinoma in which the participant has allergy or severe intolerance to carboplatin and/or cisplatin, platinum-sensitive ovarian cancer in which the participant has allergy or severe intolerance to carboplatin and/or cisplatin, platinum-sensitive primary peritoneal carcinoma in which the participant has allergy or severe intolerance to carboplatin and/or cisplatin